Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | FEN1 | P39748 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4477069 | 0.82 | MEN1 (0.46) | FEN1ALDH1A1 | |
| SCHEMBL15074670 | 0.78 | HTR1A (0.54) | HTR1ASLC6A2SLC6A4MAPK1NPC1 | |
| SCHEMBL27648901 | 0.78 | MEN1 (0.58) | FEN1ALDH1A1 | |
| SCHEMBL1340917 | 0.77 | HTR1A (0.52) | HTR1ASLC6A2SLC6A4MAPK1NPC1 | |
| SCHEMBL6408447 | 0.77 | KDM4E (0.50) | HTR1ASLC6A2SLC6A4MAPK1NPC1 | |
| SCHEMBL2891311 | 0.76 | MEN1 (0.57) | HTR1ASLC6A2SLC6A4MAPK1NPC1 | |
| SCHEMBL13422264 | 0.75 | DHODH (0.53) | NPC1MAPTRAB9AFEN1ALDH1A1 | |
| SCHEMBL11924511 | 0.74 | MAPK8 (0.54) | HTR1ASLC6A2SLC6A4MAPK1NPC1 | |
| SCHEMBL10256222 | 0.74 | P2RY1 (0.50) | HTR1ASLC6A2SLC6A4NPC1MAPT | |
| SCHEMBL30022581 | 0.74 | PTGS1 (0.49) | MAPK1NPC1RAB9AFEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867210-B2 | Aryl substituted pyrimidines | EURO-CELTIQUE S.A. (LU) | 2005-03-15 | — | — | US | disclosed |
| US-20050043305-A1 | Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof | EURO-CELTIQUE S.A. (LU) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043305-A1 | Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof | CACNA1S, CACNA1C, KYNU | HTR1A 409/4885SLC6A2 510/4885SLC6A4 643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.